Robert D. Ladner
Affiliations: | Systems Biology and Disease | University of Southern California, Los Angeles, CA, United States |
Area:
Molecular Biology, Cell BiologyGoogle:
"Robert Ladner"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Davison C, Chevallier OP, Knowlson C, et al. (2018) Abstract 3836: Imbalanced nucleotide metabolism sensitizes breast cancer cells to anthracyclines Cancer Research. 78: 3836-3836 |
| Lawler M, Gavin A, Salto-Tellez M, et al. (2015) Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program. Cancer |
| Benhaim L, Zhang W, Wakatsuki T, et al. (2015) Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer. The Pharmacogenomics Journal. 15: 235-40 |
| Wilson PM, Danenberg PV, Johnston PG, et al. (2014) Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nature Reviews. Clinical Oncology. 11: 282-98 |
| Wilson PM, Labonte MJ, Martin SC, et al. (2013) Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer Investigational New Drugs. 31: 845-857 |
| Wilson PMD, Wakatsuki T, Loupakis F, et al. (2013) Association of a polymorphism in amphiregulin with worse prognosis in metastatic colorectal cancer patients treated with cetuximab. Journal of Clinical Oncology. 31: e14543-e14543 |
| Ladner RD, Kahn M, Yang D, et al. (2013) Risk of tumor-related death in stage I-III colon cance based on gender and tumor location. Journal of Clinical Oncology. 31 |
| Lee YS, Choi I, Ning Y, et al. (2012) Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. British Journal of Cancer. 106: 1833-41 |
| Ning Y, Labonte MJ, Zhang W, et al. (2012) The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Molecular Cancer Therapeutics. 11: 1353-64 |
| Wilson PM, LaBonte MJ, Lenz HJ, et al. (2012) Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer Molecular Cancer Therapeutics. 11: 616-628 |